🚨 Ozempic Counterfeit Ring Busted! Deep Discounts & Fake Drugs Target US Buyers 💊

The U.S. Department of Justice (DOJ) has unsealed an indictment charging two Indian nationals, Roy and Ramancha, with allegedly orchestrating a scheme to smuggle counterfeit Ozempic from China into the United States. This significant bust highlights the growing threat of fake GLP-1 medications infiltrating the global supply chain, posing a serious risk to public health.

According to court documents, Roy and Ramancha, operating from July 2023 to April 2024, allegedly procured fake Ozempic from unauthorized sources in China. These counterfeit products were then distributed with sophisticated fraudulent packaging, including fake package inserts, pen labels, and needles, designed to deceive buyers into believing they were purchasing authentic medication from Novo, the manufacturer of Ozempic.

The indictment details that Ramancha executed sales agreements with companies in Lakeland and Sanford, Florida, offering the counterfeit product at "deeply discounted pricing." This strategy aimed to exploit the high demand for GLP-1 medications like Ozempic, which have seen a surge in popularity for weight loss purposes across the U.S. The seriousness of the operation was further underscored by alleged threats made by Roy in November 2023.

In a chilling message, Roy reportedly stated, "Listen i am not your friend okay? I am not that guy," adding,

I am the guy that will cut some one [expletive] head off and [expletive] peoples dead wives corpse with it.

He demanded immediate resolution to a problem, instructing, "You [expletive] up Solve the [expletive] problem.

Get the truck over there today.

Even after learning that the FDA had seized some of their distributed products, Ramancha reportedly remained unfazed. When a co-conspirator inquired if an FDA warning would impact an order for 60,000 additional units of Ozempic, Ramancha allegedly replied,

Not at all.

But you have to make sure your client are not being idiotic." This case emerges as the use of GLP-1 medications for weight loss continues to rise dramatically. A recent Gallup report indicated that 11% of U.S. adults are expected to use these medications for weight loss by 2026, a significant jump from 3% in 2024. This burgeoning market creates fertile ground for illicit operations.

Assistant Attorney General A. Tysen Duva of the DOJ's Criminal Division emphasized the gravity of the situation, stating, "Counterfeit prescription drugs - especially common ones - threaten the health and safety of every American who depends on the integrity of our pharmaceutical supply." Duva added, "These defendants allegedly exploited people's health to pay themselves.

We will keep pursuing anyone who seeks to deceive American consumers with counterfeit drugs." #OzempicScam #CounterfeitDrugs #PublicHealthAlert #DOJInvestigation